Ascites is commonly present in women with advanced-stage ovarian cancer. No standardized protocol exists for the treatment of the patient with recurrent ovarian cancer and rapidly reaccumulating malignant ascites. Palliation of symptoms is most commonly achieved through repeated paracentesis, a procedure that potentially results in injury to intra-abdominal organs, infection, and patient discomfort. Our goal was to improve patient comfort by alleviating symptoms and reducing the need for paracentesis. The Pleurx®catheter offers a number of potential advantages over traditional treatment modalities. Clearly, larger study numbers are required to quantify the morbidity associated with the Pleurx®catheter.
Hirte HW, Miller D, Tonkin K, et al.: Randomized trial of paracentesis after intraperitoneal TNF alfpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecologic Oncology. 1997; 64(1): 80-87.
2.
Lorusso V, Catino A, Gargano G, et al.: Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. European J Gynecologic Oncology. 1994; 15(1): 75-80.
3.
Ward B, Mather S, Shepherd J: The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. British J Cancer. 1988; 58(5): 658-662.
4.
Ariel IM, Oropeza R, Pack GT: Intracavitary administration of radioactive isotopes in the control of effusions due to cancer: Results in 267 patients. Cancer. 1966; 19: 1096-1102.
5.
Paladine W, Cunningham TS, Sponzo R, et al.: Intracavitary bleomycin in the management of malignant effusions. Cancer. 1976; 38(5): 1903-1908.
6.
Kefford RF, Woods RL, Fox RM, Taterall HH: Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: A randomized study. Med J Aust. 1980; 2(8): 447-448.
Ozols RF, Young RC, Speyer JL, et al.: Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982; 42(10): 4265-4269.
9.
Currie JL, Gall S, Weed JCJ, et al.: Intracavitary Corynebacterioum parvum for treatment of malignant effusions. Gynecol Oncol. 1983; 16:6-14.
10.
Bitran JD: Intraperitoneal bleomycin: Pharmacokinetics and results of a phase II trial. Cancer. 1985; 56(10): 2420-2423.
11.
Stewart JS, Hird V, Snook D, et al.: Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry. Int J Cancer. 1988; 3: 71-76.
12.
Kamada M, Sakamoto Y, Funimoto H, et al.: Treatment of malignant ascites with allogeneic and autologous lymphokine-activated killer cells. Gynecol Oncol. 1989; 34(1): 34-37.
13.
Bezwoda WR, Seymour L, Dansey R: Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer. 1989; 64(5): 1029-1033.
14.
Cherchi PL, Campiglio A, Rubathu A, et al.: Endocavitary beta-interferon in neoplastic effusions. European J Gynecol Oncol. 1990; 11(6): 477-479.
15.
Clarke-Pearson DL, Rodriguez GC, Boente M: Palliative surgery for epithelial ovarian cancer. In Rubin SC, Sutton GP (eds.): Ovarian Cancer. New York: McGraw-Hill, 1993.
16.
Lund RH, Moritz MW: Complication of Denver peritoneovenous shunting. Arch Surg. 1982; 117: 924-928.
17.
Campioni N, Pasquali Lasagni R, Vitucci C, et al.: Peritoneovenous shunt and neoplastic ascites: A five-year experience report. J Surgical Oncology. 1986; 33: 31-35.
18.
Roussel JG, Droon, BBR, Hart GAM: The Denver type for peritoneovenous shunting of malignant ascites. Surgery, Gynecology & Obstetrics. 1986; 162: 235-240.
19.
Lorentzen T, Sengelov L, Nolsoe CP, et al.: Ultrasonically guided insertion of a peritoneogastric shunt in patients with malignant ascites. ACTA Radiologica. 1995; 36(5): 481-484.
20.
Belfort MA, Stevens PJ, DeHaek K, et al.: A new approach to the management of malignant ascites. European J Surgical Oncology. 1990; 16(1): 47-53.
21.
Putnam JB, Ponn R, Olak J, et al.: A phase III trial of treatment for malignant pleural effusions: Pleurx pleural catheter (PC) versus chest tube and doxycycline sclerosis (CT-S). Chest. 1997; 112: 26S.
22.
Richard HM, Coldwell DM, Boyd-Kranis RI, et al.: Pleurx tunneled catheter in the management of malignant ascites. J Vasc Interv Radiol. 2001; 12: 373-375.
